Wrap Text
Transactions by persons discharging managerial responsibilities and persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, or the “Company”, or the “Group”)
17 June 2020
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out details of the vesting and settlement of awards granted to the executive
directors on 15 June 2018 in respect of the deferred element of the Company’s 2017 short-term
incentive (“STI”). These awards, denominated in shares, vested on 15 June 2020 and will be settled in
cash on 26 June 2020 based on the middle-market quotation of a share on 15 June 2020, being £2.68
per share. The amount settled included the value of dividends attributable to the vested shares during
the period between the date of grant and the date of vesting, being a total of 12.6 pence per share.
The table below sets out the number of shares vested for the directors who were granted awards under
the STI on 15 June 2018 together with the corresponding cash settlement.
Name Number of shares vested Cash settlement
(including dividend
equivalents)
Petrus Jurgens Myburgh 1 27 236 £76,479
Daniël Petrus Meintjes 2 45 811 £128,637
Notes:
1 As Group Chief Financial Officer, Mr Myburgh is required to build and maintain a minimum holding of shares
equivalent to a value of 200% of his annual base compensation. As that threshold had not been met,, under the
Company’s Remuneration Policy, Mr Myburgh was required to apply 50% of the net of tax value of the vested
shares to the purchase of ordinary shares in Mediclinic. As announced on 10 June 2020, Mr Myburgh purchased
7 500 shares on 8 June 2020 to fulfil this obligation.
2 Mr Meintjes was an executive director of the Company at the time the award was granted and is now a non-
executive director.
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Group Chief Financial Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in 2018 under the
Company’s short-term incentive scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 27 236
d) Aggregated
information
Aggregated volume 27 236
Price £nil
e) Date of the 15 June 2020
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Non-executive director of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in 2018 under the
Company’s short-term incentive scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 45 811
d) Aggregated
information
Aggregated volume 45 811
Price £nil
e) Date of the 15 June 2020
transaction
f) Place of the Outside a trading venue
transaction
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates
(“UAE”).
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 1 June 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day
case clinics and 21 outpatient clinics. Hirslanden operated 17 hospitals, three day case clinics and three
outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern
Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised
hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more
than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics
and 18 outpatient clinics with more than 900 inpatient beds in the UAE.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9548
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 17-06-2020 04:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
